Ahu Demir: Thank you. That’s helpful. My other question is on the PRECISION 1. Given that you expect enrollment to complete in the spring 2024, what would it mean for the top line data analysis? Are we still on track for first half of next year for data readout? And what should we expect for that top line data readouts?
Loretta Itri: Well, I don’t think anything will have changed. We anticipate completing enrollment by end of first quarter. And then as the data mature, we will report out final results as quickly as we can. I can’t commit to an exact time line because we have to see how long it takes, but you can do the math, and if we have six months of follow-up on the last patient in by end of first quarter, you can see that we probably anticipate having something to report out by end of year, early next year.
Ahu Demir: Okay, thank you. And my last question is for Scott. For FYARRO market penetration, is there anything you could communicate with us, Scott? And how much growth should we expect for the subsequent quarters?
Scott Giacobello: Yes. Thanks, Ahu. Thanks for the question. We haven’t shared market penetration information. I would say that we continue to be really pleased with how FYARRO is doing in PEComa and with what we’re hearing from physicians. I think as far as what to expect as we move up from a growth perspective, you saw that we had 6% in this quarter. We had actually in the quarter had a strong April and May and followed by a little bit of a softer June. So I think that could be for a number of reasons. We actually saw a similar situation actually last year in what was the first full quarter of launch. So I think it’s — not really able to guide on what we’ll see for the back half of the year, but I think we continue to be really positive with how the launch has gone. And I think continuing, as I mentioned in my comments, continuing to make inroads into first line should bode well for duration as we move forward.
Ahu Demir: Thank you very much for taking my questions.
Operator: One moment for our next question. And our next question will be coming from Boris Peaker. Your line is open, Boris.
Boris Peaker : Good morning, and thanks for taking my questions. My first question on FYARRO. Can you comment on what you’re actually seeing in terms of duration of therapy and how it compares to what you saw in the clinical development program?
Scott Giacobello: Yes. Thanks for the question, Boris. I mean, we haven’t shared duration data yet. I think we still want a little more time out there. As I’ve said previously, you remember when we first launched and had patients coming out of EAP, and then also with no approved therapy out there, we were kind of getting patients where they were in their patient journey, so a lot of later line patients. I think as we continue to move more in the first line, which we’ve seen happen in the first half of this year, I think that should bode well, as I mentioned, for duration, and I think we’ll have a better read in the coming quarters.
Boris Peaker : Great. And my second question is on PRECISION 1, I think you mentioned there’s 15 indications enrolled. Curious, are there any predominant indication that you’re observing, maybe endometrial or something else?
